Novel coronavirus pneumonia vaccine three phase clinical related issues academician to explain

category:Internet
 Novel coronavirus pneumonia vaccine three phase clinical related issues academician to explain


Wang Junzhi: its the protection rate obtained by comparing the number of people infected after the epidemic cycle with the number of people who didnt use the vaccine and the number of people who had the placebo.

The results of phase II clinical trial show that it is safe and effective

In terms of vaccine effectiveness, the second phase clinical trial of the new coronavirus inactivated vaccine developed by Wuhan Institute of biological products of Sinopharm showed that the positive conversion rate of neutralizing antibody reached 100% after the two doses were inoculated according to the 28 day interval procedure.

Wang Junzhi: after statistical analysis of the unblinded results, the safety and effectiveness indicators of the results achieved the expected goals and objectives of our design. It has laid a good foundation for the development of three-phase clinical practice.

Wang Junzhi: the new crown vaccine must be done in the epidemic area to complete the third phase of clinical practice, which will take some time.

In view of the slightly different reports of new coronavirus strains in Asia, Europe, North America and other places, and whether the vaccine is effective in the world, Academician Wang Jun Zhi introduced that in terms of vaccine effectiveness, there is no report on the difference of antibody reaction between different sources of new coronavirus and vaccine, and the effectiveness of new coronavirus vaccine against different sources of virus in the world still needs to be tested in clinical trials Further research.

Source: Ding Guangsheng, editor in charge of CCTV news_ NT1941